RT Journal Article
SR Electronic
A1 Alexander, Walter
T1 Etoricoxib Similar to Diclofenac in Rates of Cardiovascular Events: Results of the MEDAL Trial
JF MD Conference Express
YR 2006
FD SAGE Publications
VO 6
IS 5
SP 13
OP 14
DO 10.1177/155989770600600504
UL http://mdc.sagepub.com/content/6/5/13.abstract
AB This article presents the results of the cardiovascular outcomes Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) program. The MEDAL program consisted of pooled data from three trials conducted at 1380 sites in 46 countries: the EDGE trial (osteoarthritis, 7111 patients), the EDGE II trial (rheumatoid arthritis, 4,086 patients), and the MEDAL trial (osteoarthritis and rheumatoid arthritis, 23,504 patients). The goal of this program was to determine whether cardiovascular event rates were similar in patients treated daily with a COX-2 inhibitor (etoricoxib) compared with those treated with a widely used traditional NSAID (diclofenac).